House committee hears bill to create University of Missouri governance board for rare pediatric disease research

Representative Steinmeier, sponsor of House Bill 2740, told the House Committee on Higher Education and Workforce Development that the measure responds to families’ need for clearer, faster and more accountable rare pediatric disease research coordination.

"For those families and for ours, time matters, transparency matters, and accountability matters," the sponsor said, describing his granddaughter June’s experience with a rare condition and saying the bill would not create a new agency or appropriation but would establish a governance board inside the University of Missouri system and require an annual public report to the General Assembly.

The bill and what it would do House Bill 2740 proposes a focused governance board within the University of Missouri system to consolidate and document research activity on rare pediatric diseases, with a required public report to the General Assembly each year by Dec. 31 and a hard sunset date of June 30, 2030. The sponsor emphasized that the board would include researchers, a patient or family advocate and legislative appointees and that the bill is intended to promote coordination and measurable outcomes rather than operational micromanagement.

Why supporters say it matters University witnesses and parent advocates said the state has unique research assets, naming NextGen Precision Health and the MU Research Reactor (MURR), and that coordination can speed translational work that leads to clinical trials and therapies. Rick Baron, executive vice chancellor for health affairs and dean of the School of Medicine at the University of Missouri, testified the campuses already collaborate and that the board would "memorialize" and report that work to the legislature rather than replace existing scientific leadership. John Ruth, a parent stakeholder, urged outcome-driven work and described a "cure factory" approach focused on putting therapies into patients.

Key questions from lawmakers Committee members expressed broad support but pressed for specifics. Lawmakers asked who would appoint the patient or family advocate and how appointees would be selected and protected from conflicts of interest. Representative Allen and others questioned the role of elected officials on a body overseeing scientific work, warning about partisan influence and conflicts when industry participates. Members also debated whether a four-year sunset is sufficient for measurable research results and asked staff to clarify meeting frequency and statutory authority for any governance functions beyond reporting.

University and stakeholder responses University witnesses said they expect two to three board meetings a year, that industry partners would not serve on the board though nonprofit collaborators could, and that the annual report would give legislators a clearer picture of research activity and outcomes. Dr. Baron and others said the board’s purpose is to improve coordination, inform the legislature and support translation of research into treatments, while leaving scientific decision-making to researchers.

Public testimony Two family advocates described personal experiences with childhood cancer and genetic conditions and urged the committee to support efforts that improve navigation, accelerate research and increase visibility for pediatric research work in Missouri.

Next steps The hearing concluded without a committee vote on HB 2740; committee members indicated interest in clarifying appointment methods, conflict-of-interest safeguards and the sunset timeframe before advancing the bill.